Semantic Scholar uses AI to extract papers important to this topic.
4597Background: Patients with advanced or metastatic BTC who progress on first-line (1L) gemcitabine-based doublet chemotherapy… Expand Background Cholangiocarcinoma (CCA) is a slowly progressing but highly aggressive malignancy. Targeting the HER protein family… Expand Triple-negative breast cancer (TNBC) is a complex disease associated with the aggressive phenotype and poor prognosis. TNBC… Expand The aim of this study was to develop drug delivery nanosystems based on pegylated gold nanoparticles (PEGAuNPs) for a combination… Expand 331Background: Varlitinib is a nanomolar inhibitor of EGFR, HER2, and HER4 and has shown potent anti-tumor activity as… Expand Abstract Background VAR is a potent TKI against EGFR, HER2 and HER4. Efficacy of VAR combined with fluoropyrimidine and platinum… Expand Colloidal gold nanoparticles are targeting probes to improve varlitinib delivery into cancer cells. The nanoconjugates were… Expand 2588Background: Varlitinib (V) is a reversible inhibitor of HER1/HER2/HER4. This is a phase 1b dose confirmation study to… Expand Varlitinib is a potent, reversible pan-HER inhibitor of the ATP-binding site of EGFR (IC50 = 7 nM), HER2 (IC50 = 2 nM) and HER4… Expand Varlitinib was synthesized in total yield of 18. 2% by a seven-step reaction,using 2-chloro-4-nitrophenol and 2-amino-4… Expand